2025³â 08¿ù 28ÀÏ ¸ñ¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > »ýȰ

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

±Ù½Ã ÁøÇà ¾ïÁ¦¿Í ºí·ç¶óÀÌÆ® ÇÊÅ͸µ µ¿½Ã °¡´ÉÇÑ ¾È°æ·»Áî

¿¡½Ç·ÎÄÚ¸®¾Æ, ºí·ç¶óÀÌÆ® ÇÊÅÍ ÄÚÆÃ ¾÷±×·¹À̵å
´º½ºÀÏÀÚ: 2025-08-28

±Û·Î¹ú ¾È°æ·»Áî Àü¹® ±â¾÷ ¿¡½Ç·ÎÄÚ¸®¾Æ°¡ µðÁöÅРȯ°æ ¼Ó ¾î¸°ÀÌ ´« °Ç°­ º¸È£¸¦ À§ÇØ ±Ù½Ã ÁøÇà ¾ïÁ¦ ¾È°æ·»Áî ‘¿¡½Ç·Î ½ºÅÚ¸®½ºÆ®(Essilor Stellest)’¿Í ÇÁ¸®¹Ì¾ö ÄÚÆÃ ‘Å©¸®Àß ÇÁ¸®º¥½Ã¾Æ(Crizal Prevencia)’¸¦ ÇÔ²² Á¦¾ÈÇϸç, ±Ù½Ã ¾ïÁ¦¿Í ºí·ç¶óÀÌÆ® ÇÊÅ͸µÀ» µ¿½Ã¿¡ °æÇèÇÒ ¼ö ÀÖ´Â ¾÷±×·¹À̵å À̺¥Æ®¸¦ Àü°³ÇÑ´Ù.

ÃÖ±Ù µðÁöÅÐ ÇнÀ°ú ½º¸¶Æ® ±â±â »ç¿ëÀÌ ÀÏ»óÈ­µÇ¸ç ¾î¸°À̵éÀÇ ºí·ç¶óÀÌÆ® ³ëÃ⠽ð£ÀÌ ±ÞÁõÇϰí ÀÖ´Ù. ºí·ç¶óÀÌÆ®´Â 380~500nm ÆÄÀåÀÇ ÆÄ¶õ»ö °è¿­ °¡½Ã±¤¼±À¸·Î, ƯÈ÷ 415~455nm ´ë¿ªÀº ´«ÀÇ ÇǷθ¦ À¯¹ßÇÏ°í ¼ö¸é ÆÐÅÏÀ» ¹æÇØÇÏ´Â µî ½Ã·Â°ú °Ç°­¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù.[1]

ÀÌ¿¡ ¿¡½Ç·ÎÄÚ¸®¾Æ´Â 9¿ù 15ÀϱîÁö ‘¿¡½Ç·Î ½ºÅÚ¸®½ºÆ®’ ±¸¸Å °í°´¿¡°Ô ºí·ç¶óÀÌÆ® ÇÊÅÍ ±â´ÉÀ» °®Ãá ‘Å©¸®Àß ÇÁ¸®º¥½Ã¾Æ’ ÄÚÆÃ ¹«·á ¾÷±×·¹À̵å ÇýÅÃÀ» Á¦°øÇÑ´Ù. ‘Å©¸®Àß ÇÁ¸®º¥½Ã¾Æ’ ÄÚÆÃÀº °íµµÈ­µÈ ÇÊÅÍ ±â¼úÀ» Àû¿ëÇØ À¯ÇØÇÑ ºí·ç¶óÀÌÆ®¿Í Àڿܼ±Àº È¿°úÀûÀ¸·Î ÇÊÅ͸µÇϰí, ÇÊ¿äÇÑ °¡½Ã±¤¼±Àº ±×´ë·Î Åë°ú½ÃÄÑ Àå½Ã°£ µðÁöÅÐ ±â±â »ç¿ë ½Ã¿¡µµ ´«ÀÇ ºÎ´ãÀ» ´ú¾îÁØ´Ù.[2]

‘¿¡½Ç·Î ½ºÅÚ¸®½ºÆ®’´Â ±Ù½Ã ±³Á¤°ú ¾ïÁ¦¸¦ ÇÑ ¹ø¿¡ ÇÒ ¼ö ÀÖ´Â ¾È°æ·»Áî·Î, ¸ÅÀÏ 12½Ã°£ Âø¿ë ½Ã ±Ù½Ã ÁøÇàÀ» 67% ¾ïÁ¦ÇÑ´Ù.[3] ·»Áî Ç¥¸éÀÇ 40%¿¡ 1021°³ÀÇ ¸¶ÀÌÅ©·Î·»Áî°¡ 11°³ÀÇ ¸µ ÇüÅ·Π¹èÄ¡µÅ ±Ù½Ã¸¦ ¾ïÁ¦Çϸ鼭µµ ´ÜÃÊÁ¡ ¾È°æ·»Áî °°Àº ¼±¸íÇÑ ½Ã¾ß¸¦ Á¦°øÇÑ´Ù.[4]

¿¡½Ç·ÎÄÚ¸®¾ÆÀÇ °­¹ÎÁö ½ºÅÚ¸®½ºÆ® Á¦Ç° ´ã´ç Â÷ÀåÀº “¹æÇÐ Áß µðÁöÅÐ ±â±â »ç¿ë ½Ã°£ÀÌ ±æ¾îÁø ¾ÆÀ̵éÀº ±Ù½Ã»Ó¸¸ ¾Æ´Ï¶ó ºí·ç¶óÀÌÆ® ³ëÃâ µî º¹ÇÕÀûÀÎ ¿ä¼Ò¸¦ °í·ÁÇÑ ´« °Ç°­ °ü¸®°¡ ²À ÇÊ¿äÇÏ´Ù”¸ç “À̹ø À̺¥Æ®¸¦ ÅëÇØ »õÇбâ Àü ÀÚ³àÀÇ ´« °Ç°­À» Á¡°ËÇÏ°í ¸ÂÃãÇü ½Ã·Â °ü¸®¸¦ ½ÃÀÛÇÏ±æ ¹Ù¶õ´Ù”°í ¸»Çß´Ù.

ÇÑÆí ‘¿¡½Ç·Î ½ºÅÚ¸®½ºÆ®’¸¦ Ãë±ÞÇÏ´Â °¡±î¿î ¾È°æ¿øÀº Àü¿ë À¥»çÀÌÆ®(https://stellest.co.kr)¿¡¼­ °Ë»öÇÒ ¼ö ÀÖÀ¸¸ç, Á¦Ç°¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸´Â °ø½Ä ȨÆäÀÌÁö(https://www.essilor.com/kr-ko)¿Í ½ºÅÚ¸®½ºÆ® °ø½Ä ºí·Î±×(https://blog.naver.com/essilor_stellest)¿¡¼­ È®ÀÎ °¡´ÉÇÏ´Ù.

[1] ‘Effects of blue light blocking glasses on visual fatigue and performance.’ (Hirakawa, Y., et al., 2017). Optometry and Vision Science.
[2] Within Crizal® Range - External laboratories tests and internal technical tests in 2019 - compared to all previous generations of Crizal® coatings
[3] Áß±¹ ¿øÀú¿ì¿¡¼­ ¿¡½Ç·Î ½ºÅÚ¸®½ºÆ®¸¦ Âø¿ëÇÑ ±Ù½Ã ¾î¸°ÀÌ 54¸í°ú ¿¡½Ç·Î ·è¼ÒƼī ´ÜÃÊÁ¡ ·»Á Âø¿ëÇÑ ±Ù½Ã ¾î¸°ÀÌ 50¸íÀ» ´ë»óÀ¸·Î ÇÑ 2³â°£ÀÇ ÀüÇâÀû, ´ëÁ¶±ºÀÌ ÀÖ´Â, ¹«ÀÛÀ§ ¹èÁ¤, ÀÌÁß¸Í°Ë ÀÓ»ó½ÃÇè °á°ú. 32¸íÀÇ ¾î¸°À̵éÀÌ ¿¬¼Ó 2³â µ¿¾È ¸ÅÀÏ ÃÖ¼Ò 12½Ã°£ ¿¡½Ç·Î ½ºÅÚ¸®½ºÆ®¸¦ Âø¿ë½Ã. Bao J, Huang Y, Li X, Yang A, Zhou F, Wu J, Wang C, Li Y, Lim EW, Spiegel DP, Drobe B, Chen, H. Spectacle lenses with aspherical lenslets for myopia control vs single-vision spectacle lenses: a randomized clinical trial. JAMA ophthalmology. 2022;140(5):472-8. doi:10.1001/jamaophthalmol.2022.0401
[4] Two-year prospective, controlled, randomized, double-masked clinical trial results on 54 myopic children wearing Stellest® lenses compared to 50 myopic children wearing single vision lenses. Results based on 32 children who declared wearing Stellest® lenses at least 12 hours per day every day. Bao, J. et al. (2021). One-year myopia control efficacy of spectacle lenses with aspherical lenslets. Br. J. Ophthalmol. doi:10.1136/bjophthalmol-2020-318367.

Ãâó : ¿¡½Ç·ÎÄÚ¸®¾Æ



 Àüü´º½º¸ñ·ÏÀ¸·Î

±Ù½Ã ÁøÇà ¾ïÁ¦¿Í ºí·ç¶óÀÌÆ® ÇÊÅ͸µ µ¿½Ã °¡´ÉÇÑ ¾È°æ·»Áî
À̺êÀÚ¸® ÀÚ»ç¸ô, Å׸¶º° ¸±·¹ÀÌ ±âȹÀü ÁøÇà
ƯÇã ±â¼ú·Î ¸¸µç õ¿¬¼¼Å¹¼¼Á¦ ¡®™—¿ö½Ã¡¯ Ãâ½Ã
±Á³× µà¸Õ, ¡®µàµàµ¥ÀÌ¡¯ ÁøÇࡦ¸ÂÃãÇü È­½Ä¡¤°£½Ä ÃÊÆ¯°¡ ÇýÅÃ
LG»ýȰ°Ç°­, Çѱ¹ Ưȭ ĸ½¶¼¼Á¦ ºê·£µå ¡®Å×Å© ¼öÆÛĸ½º¡¯ Ãâ½Ã
Ç®¸®¿À, ¿ÀÇǽºÃ¼¾î ¸¶»çÁö±â ¡®¸®¿Ã·¢½º ¸ÖƼ ü¾î¡¯ ·ÐĪ
»ùÇ¥-¡®Àú¼Ó³ëÈ­ ¿ä¸® Àüµµ»ç¡¯ ÀåÀº½Ç ÆíÁýÀå, ¼îÇζóÀ̺ê ÁøÇà

 

Çϸ², ½ÅÁ¦Ç° ¡®Æ®·¯Çà ´ß¸ñ»ì ±¸ÀÌ¡¯ GS´õÇÁ·¹½Ã¿¡¼­ ÆÇ¸Å
ºñÆ®, ÀܸÁ·çÇÇ Ä÷¡¹ö·Î MZ¼¼´ë °ø·« ¼º°ø
»ùÇ¥, ²É°Ô Á¦Ã¶ ¾ÕµÎ°í ¡®¸¸´É°ÔÀå°£À塯 ÇÒÀÎ ÆÇ¸Å
Åõ½æÇ÷¹À̽º ¡®°í±¸¸¶ »ýÅ©¸² ÄÉÀÌÅ©¡¯ Ãâ½Ã
½Å³óÀÛ¼Ò, Àú¼Ó³ëÈ­ ½Ä´Ü¿¡ ÃÖÀûÈ­µÈ ¡®´À¸°È¥Çհ Ãâ½Ã
Åõ½æÇ÷¹À̽º, ¡®¿¡±× ÇÔ¹Ú ºê¸®¿À½´ ¹ø¡¯ Ãâ½Ã
À̺êÀÚ¸®, ¿Â¶óÀÎ Àü¿ë ºê·£µå ¡®¿Â-À̺êÀÚ¸®¡¯ ·ÐĪ

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚ Ç¥±â¿¡ ´ë¸¸½Ä À½Â÷ Ç¥±â '纽ÞÙó¢ ´Ï¿ì½ÃÁö' º´±â
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬ì×öõ(ÜÄÒ¬ÜØÙÌ ÜÄ...
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®¿ìºê Alliuv ä¹备: ä¹联êó备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..